Vascular Access Complications for Therapeutic Apheresis in Nephrology

Completed

• Conditions: Apheresis Related Complication; Vascular Access Complication

• Registration Number: NCT05894317
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.

Detailed Description

The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.

Complications may include arterio-veinous fistula or graft (AVF or AVG) thrombosis with or without known stenosis; AVF or AVG or central veinous catheter (CVC) infections and CVC dysfunctions.

The investigators may enroll all patients receveing therapeutic apheresis for nephrologic indications in North East France.

Nephrologics indications include :

* acute or active antibody mediated rejection (ABMR),

* Goodpasture disease,

* ANCA vasculitis,

* thrombotic microangiopathy (TMA),

* Focal segmental glomerulosclerosis (FSGS),

* HLA or ABO desensitization for kidney transplantation.

Data inclusion period is from June 2020 to June 2022.

The aim of the study is to describe the proportion and type of complication in the population of patient receving therapeutic apheresis for nephrologic disease in the North East France. Te investigators will study the risk factors that are associated with this complications.

The second aim of the study is to describe the population of patient receving therapeutic apheresis in our unit and in our region.

Study Timeline

• Study Start: 2020-06-01
• Primary Completion: 2022-06-30
• Study First Submitted: 2023-05-30
• Study First Submitted QC: 2023-05-30
• Study First Posted: 2023-06-08
• Status Verified: 2025-02
• Study Completion: 2025-02-14
• Last Update Submitted: 2025-02-21
• Last Update Posted: 2025-02-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• patients in nephrology receiveing apheresis treatment by filtration or double filtration

Exclusion Criteria

• apheresis treatment for other indications
• centrifugation apheresis treatment

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vascular access Complication (catheter or AVF/AVG thrombosis/infection) rate in therapeutic apheresis among nephrological diseases	june 2020 june 2022	Percent of patient with Vascular access Complication

Secondary Outcome Measures

Name	Time	Method
Comparison of complications rate with literature datas	june 2020 june 2022
Description of population enrolled	june 2020 june 2022	Description of population treated by therapeutic apheresis in Northeast France

Trial Locations

Locations (1)

Central Hospital; 🇫🇷 Nancy, France